This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fonseca R . Many and multiple myeloma(s). Leukemia 2003; 17: 1943–1944.
Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ . The (11;14)(q13;q32) in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113: 831–837.
Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R . t(11 ;14) and t(4 ;14) Translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032–2035.
Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.
Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132–139.
Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer H, Shima Y et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72–81.
Niklas Z, Kirchbacher K, Vesely M, Hübl W, Ludwig H . Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006; 47: 1103–1109.
Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.
van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB . Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellualr cytotoxicity. Clin Cancer Res 2006; 12: 4027–4035.
Acknowledgements
This study was supported by Roche Pharmaceuticals, Neuilly-sur-Seine, France.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Moreau, P., Voillat, L., Benboukher, L. et al. Rituximab in CD20 positive multiple myeloma. Leukemia 21, 835–836 (2007). https://doi.org/10.1038/sj.leu.2404558
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404558
This article is cited by
-
Aktuelle immuntherapeutische Ansätze beim multiplen Myelom
best practice onkologie (2019)
-
Plasma Cell Dyscrasias in India-2017 Updates
Indian Journal of Hematology and Blood Transfusion (2018)
-
Monoclonal antibody therapy in multiple myeloma
Leukemia (2017)
-
Reply to ‘Rituximab in CD20 positive multiple myeloma’ by P Moreau et al.
Leukemia (2008)
-
Rituximab in CD20 positive multiple myeloma
Leukemia (2008)